Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep:54:103104.
doi: 10.1016/j.msard.2021.103104. Epub 2021 Jun 24.

Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia

Dominika Stastna  1 , Ingrid Menkyova  2 , Jiri Drahota  3 , Aneta Mazouchova  4 , Jana Adamkova  5 , Radek Ampapa  6 , Marketa Grunermelova  7 , Marek Peterka  8 , Eva Recmanova  9 , Petra Rockova  10 , Matous Rous  11 , Ivana Stetkarova  12 , Martin Valis  13 , Marta Vachova  14 , Ivana Woznicova  15 , Dana Horakova  16
Affiliations

Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia

Dominika Stastna et al. Mult Scler Relat Disord. 2021 Sep.

Abstract

Background: When the novel coronavirus disease 2019 (COVID-19) appeared, concerns about its course in patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) arose. This study aimed to evaluate the incidence, severity and risk factors of the more severe COVID-19 course among MS and NMOSD patients.

Methods: From March 1, 2020, to February 28, 2021, 12 MS centres, representing 70% of the Czech MS and NMOSD population, reported laboratory-confirmed COVID-19 cases via the Czech nationwide register of MS and NMOSD patients (ReMuS). The main outcome was COVID-19 severity assessed on an 8-point scale with a cut-off at 4 (radiologically confirmed pneumonia) according to the World Health Organisation´s (WHO) COVID-19 severity assessment.

Results: We identified 958 MS and 13 NMOSD patients, 50 MS and 4 NMOSD patients had pneumonia, 3 MS and 2 NMOSD patients died. The incidence of COVID-19 among patients with MS seems to be similar to the general Czech population. A multivariate logistic regression determined that higher body mass index (BMI [OR 1.07, 95% CI, 1.00-1.14]), older age (OR per 10 years 2.01, 95% CI, 1.41-2.91), high-dose glucocorticoid treatment during the 2 months before COVID-19 onset (OR 2.83, 95% CI, 0.10-7.48) and anti-CD20 therapy (OR 7.04, 95% CI, 3.10-15.87) were independent variables associated with pneumonia in MS patients. Increase odds of pneumonia in anti-CD20 treated MS patients compared to patients with other disease-modifying therapy (same age, sex, BMI, high-dose glucocorticoid treatment during the 2 months before COVID-19 onset, presence of pulmonary comorbidity) were confirmed by propensity score matching (OR 8.90, 95% CI, 3.04-33.24). Reports on COVID-19 infection in patients with NMOSD are scarce, however, data available up to now suggest a high risk of a more severe COVID-19 course as well as a higher mortality rate among NMOSD patients. In our cohort, 4 NMOSD patients (30.77%) had the more severe COVID-19 course and 2 patients (15.39%) died.

Conclusion: The majority of MS patients had a mild COVID-19 course contrary to NMOSD patients, however, higher BMI and age, anti-CD20 therapy and high-dose glucocorticoid treatment during the 2 months before COVID-19 onset were associated with pneumonia. Based on this study, we have already started an early administration of anti-SARS-CoV-2 monoclonal antibodies and preferential vaccination in the risk group of patients.

Keywords: B-cell depleting therapies; COVID-19; Disease-modifying therapies; Multiple sclerosis; Neuromyelitis optica spectrum disorder.

PubMed Disclaimer

Figures

Image, graphical abstract
Graphical abstract
Figure 1
Figure 1
Absolute standardized mean difference of covariates before and after matching
See this image and copyright information in PMC

References

    1. Alonso R., Silva B., Garcea O., Diaz P.E.C., dos Passos G.R., Navarro D.A.R., Valle L.A.G., Salinas L.C.R., Negrotto L., Luetic G., Tkachuk V.A., Míguez J., de Bedoya F.H.D., Goiry L.G., Sánchez N.E.R., Burgos M., Steinberg J., Balbuena M.E., Alvarez P.M., López P.A., Ysrraelit M.C., León R.A., Cohen A.B., Gracia F., Molina O., Casas M., Deri N.H., Pappolla A., Patrucco L., Cristiano E., Tavolini D., Nadur D., Granda A.M.T., Weiser R., Cassará F.P., Sinay V., Rodríguez C.C., Lazaro L.G., Menichini M.L., Piedrabuena R., Escobar G.O., Carrá A., Chertcoff A., Pujols B.S., Vrech C., Tarulla A., Carvajal R., Mainella C., Becker J., Peeters L.M., Walton C., Serena M.A., Nuñez S., Rojas J.I. COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America. Mult. Scler. Rel. Disord. 2021;51 doi: 10.1016/j.msard.2021.102886. - DOI - PMC - PubMed
    1. Český statistický úřad, n.d.Obyvatelstvo | ČSÚ [WWW Document]. URL https://www.czso.cz/csu/czso/obyvatelstvo_lide (accessed 4.17.21).
    1. Ciampi E., Uribe-San-Martín R., Soler B., Fernández R., García P., Navarrete-Asenjo C., Miguel Tirapegui J., Torres R., Polanco J., Suárez F., José Cuello M., Cárcamo C. COVID-19 in MS and NMOSD: A multicentric online national survey in Chile. 2020. - DOI - PMC - PubMed
    1. Creed M.A., Ballesteros E., Jr L.J.G., Imitola J. Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis optica spectrum disorder. Mult. Scler. Rel. Disord. 2020;44 doi: 10.1016/j.msard.2020.102199. - DOI - PMC - PubMed
    1. Fan M., Qiu W., Bu B., Xu Y., Yang H., Huang D., Lau A.Y., Guo J., Zhang M.N., Zhang X., Yang C.S., Chen J., Zheng P., Liu Q., Zhang C., Shi F.D. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders. Neurol. Neuroimmunol. Neuroinflamm. 2020;7:787. doi: 10.1212/NXI.0000000000000787. - DOI - PMC - PubMed